Asked to rank vaccine manufacturers on five metrics, physicians produced a leaderboard that reads Pfizer, yawning gap, Merck. ZoomRx generated the ranking by asking 50 physicians to name the top ...

Sales of Padcev, a treatment for advanced bladder cancer Pfizer gained through its $43 billion deal for Seagen, also came in ahead of analysts' expectations. The Seagen deal, as well as its $4 ...

After nearly two years of legal back and forth, Pfizer and its German partner BioNTech have won a brief reprieve in their patent fight against mRNA rival Moderna. In a docket entry dated Friday ...

Shares of Pfizer and Viking Therapeutics have been on markedly different trajectories over the prior three years. In this comparison, Pfizer scans as a safer choice for cautious investors ...

Pfizer has faced numerous challenges, including a decline in COVID-19 vaccine demand and high costs, but the worst is likely priced into the stock. The company is focusing on innovation and has ...

Over the last twelve months, Pfizer's stock experienced a massive sell-off due to a massive revenue and EPS drop after the COVID-related spikes of 2021 and 2022. However, the company's financial ...

Pfizer’s cost cuts that began last year have stretched to the closure of a well-known internal R&D team that focused on partnering with physician-scientists to launch new medicines, including ...

Pfizer (NYSE: PFE) is scheduled to report its Q1 2024 results on Wednesday, May 1. We expect the company to post revenue of $13.8 billion and earnings of $0.50 on a per share and adjusted basis ...

Pfizer (NYSE: PFE) and Viking Therapeutics (NASDAQ: VKTX) perfectly embody this situation. Pfizer's shares offer a rock-bottom valuation and a sky-high dividend yield. Viking Therapeutics ...

Pfizer (NYSE: PFE) isn't exactly a hot stock right now. Since its massive run-up during the pandemic's height, built on hopes for its coronavirus vaccine, new sources of growth haven't led to ...

Pfizer has been struggling since its coronavirus vaccine sales started to fall. It's making a big move into cancer drugs, which should help it diversify. There are more tough times ahead, but they ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 second-quarter 2024 dividend on the company’s common stock, payable June 14 ...